ORIC PHARMACEUTICALS INC's ticker is ORIC and the CUSIP is 68622P109. A total of 84 filers reported holding ORIC PHARMACEUTICALS INC in Q2 2023. The put-call ratio across all filers is 2.93 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $291,344 | -33.2% | 48,156 | -14.3% | 0.00% | – |
| Q2 2023 | $435,879 | -18.9% | 56,170 | -40.4% | 0.00% | – |
| Q1 2023 | $537,618 | +510.9% | 94,319 | +242.3% | 0.00% | – |
| Q3 2022 | $88,000 | -68.6% | 27,557 | -55.8% | 0.00% | – |
| Q2 2022 | $280,000 | -13.0% | 62,387 | +3.5% | 0.00% | – |
| Q1 2022 | $322,000 | -50.1% | 60,306 | +37.3% | 0.00% | – |
| Q4 2021 | $645,000 | -23.7% | 43,915 | +8.6% | 0.00% | – |
| Q3 2021 | $845,000 | +41.8% | 40,421 | +19.9% | 0.00% | – |
| Q2 2021 | $596,000 | -7.6% | 33,703 | +28.1% | 0.00% | – |
| Q1 2021 | $645,000 | +7.0% | 26,320 | +47.7% | 0.00% | – |
| Q4 2020 | $603,000 | +77.9% | 17,822 | +31.6% | 0.00% | – |
| Q3 2020 | $339,000 | -2.0% | 13,544 | +32.0% | 0.00% | – |
| Q2 2020 | $346,000 | – | 10,264 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | 602,272 | $3,643,746 | 14.84% |
| Column Group LLC | 3,568,181 | $21,587,495 | 14.33% |
| Nextech Invest Ltd. | 4,285,714 | $25,928,570 | 7.86% |
| Prosight Management, LP | 2,579,802 | $15,607,802 | 4.95% |
| Invus Financial Advisors, LLC | 1,007,575 | $6,095,829 | 3.82% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 1,123,345 | $6,796,237 | 2.06% |
| VR Adviser, LLC | 2,142,856 | $12,964,279 | 1.36% |
| Altium Capital Management LP | 418,706 | $2,533,171 | 1.32% |
| Euclidean Capital LLC | 1,978,820 | $11,971,862 | 1.31% |
| Frazier Life Sciences Management, L.P. | 2,142,855 | $12,964,273 | 0.86% |